Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
1996
Size (employees)
139 (est)
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Sanda-shi, JP
4-1 Techno-Park
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
Chiyoda, JP
NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
Kita Ward, JP
Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
Zug, CH
22 Baarerstrasse
Show all (7)

Sucampo Pharmaceuticals Data and Metrics

Sucampo Pharmaceuticals Financial Metrics

Sucampo Pharmaceuticals's revenue was reported to be $56.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

56.3 m

Gross profit (Q1, 2017)

39.4 m

Gross profit margin (Q1, 2017), %

70%

Net income (Q1, 2017)

4.6 m

EBIT (Q1, 2017)

10.9 m

Market capitalization (21-Sep-2017)

547.4 m

Cash (31-Mar-2017)

243.5 m
Sucampo Pharmaceuticals's current market capitalization is $547.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

89.6 m115.5 m153.2 m230.1 m

Revenue growth, %

29%33%50%

Cost of goods sold

12.4 m16.3 m36.7 m76 m

Gross profit

77.2 m99.2 m116.4 m154.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

24.1 m31.5 m29.5 m34.9 m33.4 m47.2 m52 m57.9 m56.3 m

Cost of goods sold

3.8 m5 m6.1 m7.3 m5.3 m23.3 m20.4 m15.6 m16.9 m

Gross profit

20.3 m26.5 m23.4 m27.6 m28.2 m23.9 m31.6 m42.3 m39.4 m

Gross profit Margin, %

84%84%79%79%84%51%61%73%70%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.1 m71.6 m108.3 m198.3 m

Accounts Receivable

5.4 m5.3 m22.8 m43 m

Inventories

4 m3.4 m8.9 m23.5 m

Current Assets

113.4 m122.3 m251.4 m307.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53.5 m56.1 m59.6 m71.3 m91.5 m130.1 m128 m128.5 m243.5 m

Accounts Receivable

4.8 m8.5 m8.2 m8.2 m6.7 m16.1 m18.2 m20.7 m20.5 m

Inventories

423 k133 k328 k308 k296 k24.4 m21.6 m24.2 m23 m

Current Assets

119.3 m124.1 m120.9 m136.7 m161.4 m228.1 m237.7 m237.5 m322.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.4 m13.1 m33.4 m18.5 m

Depreciation and Amortization

1.5 m10.6 m45.7 m

Accounts Receivable

(4 m)(8.5 m)(18.8 m)

Inventories

(163 k)(1.4 m)(1.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

1.6 m1.5 m6.4 m9.6 m7.2 m(4.1 m)(832 k)8.1 m4.6 m

Accounts Receivable

4.8 m8.5 m8.2 m8.2 m6.7 m16.1 m18.2 m20.7 m20.5 m

Inventories

423 k133 k328 k308 k296 k24.4 m21.6 m24.2 m

Accounts Payable

5.6 m5.9 m1.4 m3.9 m4.9 m5.1 m6.2 m7.9 m8 m
USDY, 2017

Revenue/Employee

404.9 k

Financial Leverage

3 x
Show all financial metrics

Sucampo Pharmaceuticals Market Value History

Traffic Overview of Sucampo Pharmaceuticals

Sucampo Pharmaceuticals Online and Social Media Presence

Sucampo Pharmaceuticals Company Life and Culture

You may also be interested in